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Aims: Premature discontinuation of antiplatelet therapy has been iden-
tified as a major risk factor for stent thrombosis and prior aspirin
withdrawal has been associated with poor prognosis after acute coronary
syndrome. We investigated the hypothesis that biological aspirin “resis-
tance” may often be related to non compliance in patients undergoing
coronary stenting.
Methods and Results: We prospectively investigated the occurrence of
aspirin non compliance in 136 consecutive patients undergoing coronary
stenting receiving aspirin 75 mg daily. We analyzed post-treatment
maximal intensity of arachidonic acid-induced platelet aggregation (AA-
Ag) during hospitalization after controlled intake of aspirin and one month
after hospital discharge. After one month, all non responders received con-
trolled aspirin 75 mg and assessment of response was repeated. Aspirin
non response was defined by AA-Ag>30%. During in-hospital period, the
range of AA-Ag varied from 0 to 34% with a mean value of 7.5±10 % and
4 patients (3%) were classified as non responders. One month after dis-
charge, AA-Ag of the population was significantly higher than during the
hospital phase (15.3±23 vs 7.5±10%, p=0.0004) and 19 patients (14%)
were identified as non responders. After controlled administration of
aspirin, all but one of these “non responders” became responders and were
identified as patients with non compliance rather than biological resis-
tance.
Conclusion: Aspirin resistance is rare in compliant patients using methods
that directly indicate the degree of platelet cyclooxygenase inhibition. More
than 10% of patients receiving aspirin for coronary stenting are non compliant
for aspirin therapy during the first month after stenting. These results suggest
a need for improved education of these patients.
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Aim: In STEMI, controversial data exist on the relative importance of
patient-dependent time (Symptom-Onset (SO) to first medical contact (FMC))
and Transfer Time (TT=time from FMC to sheath insertion). We assessed the
impact of TT on in-hospital (IH) mortality in a well organized urban network
using Mobile Intensive Care Units (MICU).
Methods: In a web-based registry (e-PARIS), we evaluated delay in care
of 705 consecutive STEMI patients transferred to the Pitié-Salpêtrière cath-lab
for primary PCI.
Results: Population was 63±14 y/o, 75.6% were male, 46.9% had anterior
MI, 16.7% were in Killip class 2, and 3.8% had out-of-hospital cardiac arrest.
Abciximab was used in 82.4%, radial approach in 87.7% and stenting in
89.7% of patients. Median time (IQR) from SO to FMC was 110 (248) min
(102 (190) min when FMC was MICU and 160 (381) min when FMC was a
referring hospital, p<0.0001). Median TT was 104 (75) min (95 (45) min for
MICU and 151 (178 )min for patients transferred from a primary hospital,
p<0.0001). When divided into quartiles, increasing TT was associated with
higher IH mortality. This relation to IH mortality was striking in patients pre-
senting early (within 2 hours of SO), and not significant in late presenters (>2
hours of SO) (fig). After adjustment for baseline characteristics, TT was not
associated with mortality anymore suggesting that the sicker patients had the
longest TT.
Conclusions: The association between TT and early mortality is strongly
dependent on patients’ characteristics and time to presentation. After adjust-
ment for these parameters, TT does not appear to be a major contributor of IH
mortality in a well organized urban network for primary PCI. Improving time-
to-first medical contact may be more critical.
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Background: The *2 variant of the CYP2C19 gene encodes a defective
enzyme that likely fails to adequately convert clopidogrel to its active metabo-
lite, leading to diminished cardiovascular protection.
Objectives: We performed a meta-analysis of trials that determined the
CYP2C19*2 genetic variant in patients exposed to clopidogrel therapy after
stent implantation. The primary objective was to evaluate whether carriage of
the CYP2C19*2 was associated with the occurrence of stent thrombosis, recur-
rent myocardial infarction and cardiovascular death.
Methods and results: Eight trials (9427 patients) with data available data
on death, recurrent myocardial infarction, stent thrombosis and any ischemic
events were selected. The odds ratio (OR) as the parameter of efficacy with a
fixed effect model was used. Carriers of the genetic variant associated with a
loss-of-function of the CYP2C19 enzyme (28%, n=2674) displayed a 30%
increase in the risk in any ischemic events compared to non carriers (10.4% vs
8.3%) (OR, 1.31; 95% CI, 1.12-1.53; p<0.001). This metanalysis confirmed
the excess of stent thrombosis (2.9% vs 0.9%) (OR 3.01; 95% CI: 1.89-4.80,
p<0.001)(n=4975) but also of death or MI (12.1% vs 5.3%)(OR 2.51; 95% CI:
2.07-3.05, p<0.001)(n=7022). This single gene variant (CYP2C19*2) was also
associated with an excess of cardiovascular mortality (1.8% vs 1.0%)(OR
1.79; 95% CI: 1.10-2.91, p<0.019)(n=6225).
Conclusions: Our findings support rapid genetic testing for the
CYP2C19*2 to identify patients with a deficient clopidogrel metabolic activa-
tion. The clinical relevance of such approach remains to be established by ade-
quately powered randomized studies.
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 Purpose: The present observational study compares in-hospital and 12
month clinical outcomes in elderly patients (aged ≥ 75 years) with unprotected
left main coronary artery (ULMCA) disease treated either with coronary artery
bypass grafting (CABG) or drug eluting stent (DES).
Methods: From January 2004 to December 2007, 211 patients (pts) with
ULMCA stenosis, aged 75 or older, underwent a coronary revascularisation
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